TXG // 10x Genomics Inc.

DES <GO> NASDAQ CIK 0001770787 ↗

Health Care • Biotechnology: Laboratory Analytical Instruments

$81.55 ▼ -2.07 (-2.47%)

MKT CAP: $10.63B • VOL: 1.86M

52W L $13 52W H $103

ALTMAN Z

25.02 SAFE

PIOTROSKI

8 / 9

TXG // ROARABLE RATING & 5-PILLAR RQD CONFIDENCE 02:00 EST DETERMINISTIC ENGINE

PRIOR: RQD 65/100 [C] (+0 PT) • UNCHANGED AS OF 2026-11-01

ROARABLE C

RQD CONFIDENCE

65 / 100 +0D

5 X 20-PT QUANT PILLARS

E 0 D 35 C 59 B 70 A 86+

Roarable Hold — Fair / Balanced Risk-Reward

01 MASSIVE / SEC XBRL

Forensic Fundamentals

13 / 20

SOLID

FCF +200% vs NI +76.2% • ROIC-WACC -15.8% • Z 25.02

02 OPRA GEX + SEC 13F

Whale & Options Flow

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

03 SEC FORM 4 (90D)

Insider Conviction

[LOCKED] FLAGGED

UNLOCK BELOW TO REVEAL

04 FRED 90D r-MATRIX

Macro Regime Fit

17 / 20

STRONG

TAILWIND • r(10Y)=+0.00 (+23bp) • r(OAS)=+0.00

05 10-K REDLINE AUDIT

Forensic 10-K Risk

13 / 20

SOLID

20 BASE - 7 DEDUCT • 0 CRIT / 0 MED • STABLE

ALERT

Why did TXG's Whale & Options Flow & Insider Conviction sub-score just flash a warning? Enter your email to unlock the full 5-Pillar Rating Breakdown + get instant alerts whenever TXG is Upgraded or Downgraded.

SIG <GO> CROSS-FEED TRIANGULATION // PROPRIETARY ANOMALY ENGINE (1 ACTIVE ON TXG)

STAGE 2 DETERMINISTIC Z-SCORE + STAGE 3 GEEK DESK BRIEF ALL MARKET ANOMALIES <SIG>

▼ BEARISH // F-RATED EARNINGS MIRAGE // ACCRUAL WATCHSIFTER 02 // ACCRUAL & RECEIVABLES FORENSICS

SEVERITY: 93/100 Z-SCORE: +3.37σ

TXG Accounting Gap: Net Income (+76.2%) Outpaced OCF (+220%) With +131.9% Working-Capital Build

CASH CONVERSION GAP

-143.8% (NI vs OCF)

RECEIVABLES / WC BLOAT

+131.9% VS REV

60D C-SUITE FORM 4 SALES

0 OPEN-MKT DUMPS

[GEEK DESK FORENSIC NOTE // SEC XBRL × FORM 4 CROSS-CHECK]

SEC EDGAR XBRL CompanyFacts10-K/10-Q Working Capital ScheduleSEC Form 4 Executive Sales

SEC EDGAR XBRL triangulation on 10x Genomics Inc. (TXG) exposes a +-143.8% Cash Conversion Gap as YoY Net Income growth (+76.2%) diverged from Operating Cash Flow growth (+220.0%). Non-cash current assets and receivables expanded +131.9% relative to top-line revenue growth. Monitor upcoming 10-Q cash realization closely for accrual mean-reversion.

TXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +217.96%🛡️ HOLDING TREND SUPPORT

2026-10-30O $73.65H $75.79L $67.42C $70.11VOL 5.22M

RES: $116.5SUP: $69.84SMA50: $74.17SMA200: $40.57

TXG // INSTITUTIONAL BULL VS. BEAR FORENSIC DEBATE

UNDERWEIGHT CONVICTION: 37/100

BEAR 0

100 BULL

10x Genomics Inc. (TXG) exhibits 69.1% gross margins and -5.7% return on invested capital within Health Care (Biotechnology: Laboratory Analytical Instruments), balanced against a 24.0x enterprise multiple and 7.4% implied options volatility.

▲ INSTITUTIONAL BULL THESIS (LONG)

01. Operating Leverage & Capital Efficiency Moat

Sustained 69.1% gross profitability converts into -9.5% operating margin and -5.7% ROIC, outpacing sector cost of capital.

ROIC: -5.7% // GM: 69.1%

02. Top-Line Expansion & Cash Conversion

YoY revenue trajectory of +5.2% paired with 1.22% free cash flow yield supports self-funded R&D and capital return.

REV YOY: +5.2% // FCF YLD: 1.22%

03. Balance Sheet Solvency & Forensic Quality

Altman Z-Score of 25.02 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.

ALTMAN Z: 25.02 // F-SCORE: 8/9

▼ INSTITUTIONAL BEAR THESIS (SHORT / RISK)

01. Multiple Compression & Duration Sensitivity

Trading at 24.0x trailing P/E (24.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.

P/E: 24.0x // EV/EBITDA: —

02. Options Skew & Event Volatility Risk

Options market prices a ±7.4% implied move with a 1.02 put/call ratio around $80.00 max pain.

IMPL MOVE: ±7.4% // P/C: 1.02

03. Competitive Margin & CapEx Cycle Pressure

Elevated industry capital intensity and customer concentration in Biotechnology: Laboratory Analytical Instruments require continuous execution to defend -6.8% net margins.

NET MARGIN: -6.8% // D/E: 0.13x

KEY CATALYST // Upcoming 10-Q/10-K XBRL margin progression, guidance revision vs 24.0x forward consensus, and institutional 13F positioning.

MACRO REGIME // Monitor US 10Y Real Yields (DFII10) and High-Yield Credit Spreads (OAS) for beta-adjusted multiple impact (Beta 1.15).

FORM 4 & 13F FLOW OPEN OWN <GO>

FILER	SIDE	$ VALUE
INSPECT FULL OWNERSHIP LEDGER IN OWN <GO>

UNUSUAL OPTIONS TAPE OPEN OPT <GO>

STRIKE / EXP	TYPE	PREMIUM
INSPECT GEX & CHAIN IN OPT <GO>

KEY VALUATION & PROFITABILITY RATIOS XBRL FA <GO>

TRAILING P/E —

FORWARD P/E 24.0x

EV / EBITDA —

FCF YIELD 1.22%

GROSS MARGIN 69.1%

OPERATING MARGIN -9.5%

NET MARGIN -6.8%

ROIC % -5.7%

REV GROWTH YOY +5.2%

DILUTED EPS TTM $-0.33

DEBT / EQUITY 0.13x

DIVIDEND YIELD 0.00%

RSI-14 MOMENTUM 44.5

5Y EQUITY BETA 1.15

FRED MACRO SENSITIVITY (PEARSON r) ECST <GO>

MACRO CORRELATION CALIBRATION ACTIVE BELOW.

FRED MACRO REGIME STRESS-TEST SIMULATOR // TXGPEARSON R VARIANCE ENGINE

01 // SELECT FEDERAL RESERVE & CREDIT SHOCK SCENARIO

02 // POSITION NOTIONAL EXPOSURE

HEADLINE STRESS SCORE

75/100SEVERE DRAWDOWN PRESSURE

PRIMARY FACTOR EXPOSURE

DFII10 // -0.61 r

Latest: 2.08%

EST. DIRECTIONAL MOVE

-8.50%

Implied Px: $74.62

EST. DOLLAR VARIANCE

-$4,248

On $50,000 Notional

[LOCKED // MULTI-FACTOR DRAWDOWN HEDGE & MACRO TRIGGER ALERT]

Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TXG & activate live FRED threshold breach alerts.

HEAD-TO-HEAD PEER COMPARISONS COMP <GO>

TXG VS LLY

MARGINS ROIC VALUATION

TXG VS JNJ

MARGINS ROIC VALUATION

TXG VS ABBV

MARGINS ROIC VALUATION

TXG VS UNH

MARGINS ROIC VALUATION